In AD, CMA dysfunction has been linked to reduced expression and impaired assembly of the lysosomal receptor LAMP-2A, resulting in inefficient clearance of tau and other neurotoxic proteins [146]. This evidence concerns the gene MAPT and Alzheimer disease.